Investors

investor people image

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Osiris Therapeutics, Inc. Announces GrafixPL PRIME™ Launches October 1, 2018
COLUMBIA, Md. , Sept. 17, 2018 (GLOBE NEWSWIRE) -- Osiris Therapeutics, Inc. (NASDAQ: OSIR), a regenerative medicine company focused on developing and marketing products for wound care, orthopedics, and sports medicine, announces that GrafixPL PRIME™, a human placental membrane that can be stored
View HTML
Toggle Summary Osiris Therapeutics, Inc. Announces Peer-Reviewed Publication Comparing the Efficacy of Viable Cryopreserved Placental Membranes to Human Fibroblast-Derived Dermal Substitute in the Treatment of Chronic Diabetic Foot Ulcers (DFUs) in a Multicenter Randomi
COLUMBIA, Md. , Aug. 27, 2018 (GLOBE NEWSWIRE) -- Osiris Therapeutics, Inc.  (NASDAQ: OSIR), a regenerative medicine company focused on developing and marketing products for wound care, orthopedics, and sports medicine, announced today that a new peer-reviewed manuscript entitled “A multicenter,
View HTML
Toggle Summary Osiris Therapeutics, Inc. to Re-list on The Nasdaq Global Market on August 1, 2018
COLUMBIA, Md. , Aug. 01, 2018 (GLOBE NEWSWIRE) -- Osiris Therapeutics, Inc. (NASDAQ: OSIR), a regenerative medicine company focused on developing and marketing products for wound care, orthopedics, and sports medicine, today announced that The Nasdaq Stock Market LLC has approved its application to
View HTML
Toggle Summary Osiris Announces Enrollment of Patients in a Clinical Trial Evaluating GrafixPL PRIME™ in the Treatment of Chronic Venous Leg Ulcers
COLUMBIA, Md. , July 11, 2018 (GLOBE NEWSWIRE) -- Osiris Therapeutics, Inc. (OTC Pink:OSIR), a regenerative medicine company focused on developing and marketing products for wound care, orthopedics, and sports medicine, announced the initiation of its “Multicenter, Prospective, Randomized,
View HTML
Toggle Summary Osiris Announces Implementation of Prestige Lyotechnology℠ Preservation Method Allowing Ambient Storage of Living Tissues
COLUMBIA, Md. , June 04, 2018 (GLOBE NEWSWIRE) -- Osiris Therapeutics, Inc. (OTC Pink:OSIR), a regenerative medicine company focused on developing and marketing products for wound care, orthopedics, and sports medicine, announced today the implementation of Prestige Lyotechnology for manufacturing
View HTML
Toggle Summary Osiris Announces New Peer-Reviewed Publication Summarizing Clinical Outcomes of Viable Cryopreserved Placental Membranes for Management of Chronic Diabetic Foot Ulcers in Real World Setting
COLUMBIA, Md. , April 25, 2018 (GLOBE NEWSWIRE) -- Osiris Therapeutics, Inc. (OTC Pink:OSIR), a regenerative medicine company focused on developing and marketing products for wound care, orthopedics, and sports medicine, announced today that a new peer-reviewed manuscript entitled “Effectiveness of
View HTML
Toggle Summary Osiris Therapeutics to Present Clinical and Scientific Studies at Symposium on Advanced Wound Care and Wound Healing Society Spring Conference
Experts to host a variety of presentations from April 25 – April 29, 2018, in Charlotte, North Carolina COLUMBIA, Maryland , April 24, 2018 (GLOBE NEWSWIRE) -- Osiris Therapeutics, Inc. (OTC Pink Sheets:OSIR), a leading regenerative medicine company focused on developing and marketing products for
View HTML
Toggle Summary Osiris Appoints Willi Miesch to its Board of Directors, Change in CEO
COLUMBIA, Md. , Feb. 06, 2018 (GLOBE NEWSWIRE) -- Osiris Therapeutics, Inc. (Pink Sheets:OSIR) is pleased to announce that its Board of Directors, at a Board Meeting on February 6 th , 2018, appointed Mr. Willi Miesch as a Director, upon recommendation of the Nominating Committee.  Mr.
View HTML
Toggle Summary Osiris Therapeutics, Inc. Announces Resolution of SEC Investigation
COLUMBIA, Md. , Nov. 02, 2017 (GLOBE NEWSWIRE) -- Osiris Therapeutics, Inc. (OTC Pink:OSIR) (the "Company"), a leading regenerative medicine company focused on developing and marketing products for wound care, orthopedics, and sports medicine, today announced the resolution of the previously
View HTML
Toggle Summary Osiris Therapeutics, Inc. Provides Update on Audit of 2015 and 2016 Financial Statements
COLUMBIA, Md. , Oct. 30, 2017 (GLOBE NEWSWIRE) -- Osiris Therapeutics, Inc. (OTC Pink:OSIR) (the "Company"), a leading regenerative medicine company focused on developing and marketing products for wound care, orthopedics, and sports medicine, today provided an update regarding the status of the
View HTML